Literature DB >> 15365146

Salvage PCV chemotherapy for temozolomide-resistant oligodendrogliomas.

V H J M Triebels1, M J B Taphoorn, A A Brandes, J Menten, M Frenay, A Tosoni, J M Kros, E Biemond-ter Stege, R H Enting, A Allgeier, I van Heuvel, M J van den Bent.   

Abstract

The authors investigated the results of PCV chemotherapy within a cohort of 24 patients treated within the EORTC study 26971 on temozolomide chemotherapy in recurrent oligodendroglioma. The genotype of the tumors was assessed with fluorescent in situ hybridization with locus specific probes for the region 1p36. Four of the 24 patients responded (17%). Fifty percent of patients were still free from progression at 6 months and 21% were free from progression at 12 months. Although a clear relation existed between loss of 1p and response to temozolomide chemotherapy, this relation was absent in salvage PCV chemotherapy.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15365146     DOI： 10.1212/01.wnl.0000137049.65631.db

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


  18 in total

1.  Central nervous system cancers.

Authors:  Louis Burt Nabors; Mario Ammirati; Philip J Bierman; Henry Brem; Nicholas Butowski; Marc C Chamberlain; Lisa M DeAngelis; Robert A Fenstermaker; Allan Friedman; Mark R Gilbert; Deneen Hesser; Matthias Holdhoff; Larry Junck; Ronald Lawson; Jay S Loeffler; Moshe H Maor; Paul L Moots; Tara Morrison; Maciej M Mrugala; Herbert B Newton; Jana Portnow; Jeffrey J Raizer; Lawrence Recht; Dennis C Shrieve; Allen K Sills; David Tran; Nam Tran; Frank D Vrionis; Patrick Y Wen; Nicole McMillian; Maria Ho
Journal:  J Natl Compr Canc Netw       Date:  2013-09-01       Impact factor: 11.908

2.  Neuro-oncology in a nutshell.

Authors:  Joachim M Baehring
Journal:  J Neurooncol       Date:  2005-01       Impact factor: 4.130

Review 3.  Update on treatment strategies for anaplastic glioma: a review of literature.

Authors:  G Simonetti; P Gaviani; A Innocenti; A Botturi; E Lamperti; A Silvani
Journal:  Neurol Sci       Date:  2014-05-25       Impact factor: 3.307

Review 4.  Chemotherapy in glioma.

Authors:  Walter Taal; Jacoline E C Bromberg; Martin J van den Bent
Journal:  CNS Oncol       Date:  2015-04-23

Review 5.  Practice changing mature results of RTOG study 9802: another positive PCV trial makes adjuvant chemotherapy part of standard of care in low-grade glioma.

Authors:  Martin J van den Bent
Journal:  Neuro Oncol       Date:  2014-10-29       Impact factor: 12.300

Review 6.  Optimal role of temozolomide in the treatment of malignant gliomas.

Authors:  Roger Stupp; Martin J van den Bent; Monika E Hegi
Journal:  Curr Neurol Neurosci Rep       Date:  2005-05       Impact factor: 5.081

7.  Intra-arterial chemotherapy with osmotic blood-brain barrier disruption for aggressive oligodendroglial tumors: results of a phase I study.

Authors:  Daniel J Guillaume; Nancy D Doolittle; Seymur Gahramanov; Nancy A Hedrick; Johnny B Delashaw; Edward A Neuwelt
Journal:  Neurosurgery       Date:  2010-01       Impact factor: 4.654

8.  Temozolomide in malignant glioma.

Authors:  Gregor Dresemann
Journal:  Onco Targets Ther       Date:  2010-09-07       Impact factor: 4.147

Review 9.  The role of chemotherapy for pure and mixed anaplastic oligodendroglial tumors.

Authors:  Erin M Dunbar
Journal:  Curr Treat Options Oncol       Date:  2009-04-18

Review 10.  Pharmacotherapy for adults with tumors of the central nervous system.

Authors:  Nina F Schor
Journal:  Pharmacol Ther       Date:  2008-11-27       Impact factor: 12.310
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.